US Edition
Research Capital analyst Andre Uddin keeps “Speculative Buy” rating on Sernova Biotherapeutics
Summary by Cantech Letter
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Research Capital analyst Andre Uddin keeps “Speculative Buy” rating on Sernova Biotherapeutics
Research Capital analyst Andre Uddin maintained a “Speculative Buy” rating and C$0.60 price target on Sernova Biotherapeutics (Sernova Biotherapeutics Stock Quote, Chart, News, Analysts, Financials TSXV:SVA) in a June 16 report, citing strong early clinical results and a promising pipeline, but warning the company will need to secure more funding in the near term. Sernova […] Source
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
